Trinity College Dublin


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Kumlesh Dev

Professor (Physiology)
BIOMEDICAL SCIENCES INSTITUTE

Professor (Trinity Inst. of Neurosciences (TCIN))


  Drug Targets   Glutamate Receptors   Multiple Sclerosis   Neuroscience   Parkinson's Disease   Protein-Protein Interactions   Receptor Trafficking   Sphingosine 1-phosphate receptors
Details Date
Representative Director Ireland, Venture Valuation AG, Zurich, Switzerland
Details Date From Date To
Board Member of Journal of Biological Chemistry
Editorial Board Member of Canadian Journal of Pure and Applied Sciences
Pritchard, AJ, Mir, AK, Dev, KK, Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures, PLOS ONE, 9, (6), 2014, p0099444-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Sheridan, GK, Dev, KK, Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations, SCIENTIFIC REPORTS, 4, 2014, p5051-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Muirhead, G, Dev, KK, The Expression of Neuronal Sorting Nexin 8 (SNX8) Exacerbates Abnormal Cholesterol Levels, JOURNAL OF MOLECULAR NEUROSCIENCE, 53, (1), 2014, p125-134 , Journal Article, PUBLISHED  DOI
Dutta, P., O'Connell, K.E., Ozkan, S.B., Sailer, A.W., Dev, K.K., The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell deat, Journal of Neurochemistry, 2014, Journal Article, IN_PRESS  DOI
Shrestha, R., Millington, O., Brewer, J., Dev, K.K., Bushell, T.J., Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways, Neuropharmacology, 76, (a), 2014, p184-193 , Notes: [ ], Journal Article, PUBLISHED  DOI
Elain, G, Jeanneau, K, Rutkowska, A, Mir, AK, Dev, KK, The Selective Anti-IL17A Monoclonal Antibody Secukinumab ( AIN457) Attenuates IL17A-Induced Levels of IL6 in Human Astrocytes, GLIA, 62, (5), 2014, p725-735 , Journal Article, PUBLISHED  DOI
O'Connell, KE, Thakore, J, Dev, KK, Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine, SCHIZOPHRENIA RESEARCH, 156, (1), 2014, p1-8 , Journal Article, PUBLISHED  DOI
Frei, P., Dev, K.K., Drug dealers: $20 trillion of in-licensing payments (Editorial), Drug Discovery Today, 18, (21-22), 2014, p1027-1029 , Journal Article, PUBLISHED  DOI
O'Connell, K.E., Frei, P. , Dev, K.K., The premium of a big pharma license deal, 2014, - 617-619, Miscellaneous, PUBLISHED  DOI
O'Connell K, Thakore J, Dev KK, Levels of S100B are raised in female patients with schizophrenia., BMC psychiatry, 13, 2013, p146 , Journal Article, PUBLISHED  TARA - Full Text
  

Page 1 of 8

  

Research is based on investigating mechanisms that control receptor surface expression and thereby receptor function. With an interest in Multiple Sclerosis and Parkinson's Disease, we are investigating surface expression of receptors that are drug targets for these diseases, including sphingosine 1-phosphate receptors (S1P-R), parkin-associated endothelial like receptor (PAEL-R) and the interleukin 2 receptor (IL2-R). Our approach is to engineer, formulate and chemically re-design competitive blocking peptides and discover small molecular weight compounds, which alter receptor surface expression and function in vivo. Development of such agents permits cell-selective receptor modulation and the regulation of orphan receptors or difficult-to-target receptors. We are funded in kind and in part by Trinity College Dublin, Science Foundation Ireland, Health Research Board Ireland, Enterprise Ireland, The Wellcome Trust, Lundbeck, Actelion, Servier and Novartis.